Clinical data | |
---|---|
Other names | [6-[6-[6-[[12,14-dihydroxy- 10,13-dimethyl- 17-(5-oxo-2H-furan-3-yl)- 1,2,3,4,5,6,7,8,9,11,12,15,16,17- tetradecahydrocyclopenta[a]phenanthren- 3-yl]oxy]- 4-hydroxy- 2-methyloxan- 3-yl]oxy- 4-hydroxy- 2-methyloxan-3-yl]oxy- 2-methyl- 3-[3,4,5-trihydroxy- 6-(hydroxymethyl)oxan-2-yl]oxyoxan- 4-yl] acetate |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, intravenous |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.037.754 |
Chemical and physical data | |
Formula | C49H76O20 |
Molar mass | 985.127 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Lanatoside C (or isolanid) is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). Lanatoside C can be used orally[1] or by the intravenous route.[2] It is marketed in a number of countries and is also available in generic form.[3] Its main indications are rapid response atrial fibrilation and paroxysmal supraventricular tachycardia,[citation needed] two common types of arrhythmia.
It is found in Digitalis lanata.[4]